|
Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia
|
Jun 2015
|
Bone Marrow Transplant
|
aplastic anemia
|
|
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
|
Jan 2017
|
Am Soc Clin Oncol Educ Book
|
myelodysplastic syndromes (MDS)
|
|
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes
|
Jun 2016
|
Am Soc Clin Oncol Educ Book
|
myelodysplastic syndromes (MDS)
|
|
Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
|
Jan 2017
|
Ther Adv Hematol
|
myelodysplastic syndromes (MDS)
|
|
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
|
Aug 2020
|
Lancet Hematology
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy
|
Jun 2017
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
|
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis.
|
Jun 2013
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review
|
Jul 2023
|
Experimental Hematology & Oncology
|
myelodysplastic syndromes (MDS)
|
|
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
|
Mar 2021
|
Cancers
|
chronic myelomonocytic leukaemia (CMML), myelodysplastic syndromes (MDS)
|
|
Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?
|
Feb 2014
|
Expert Rev Hematol
|
myelodysplastic syndromes (MDS)
|
